• Home Dutch
  •  EN 
  • Employee login

Publications KFF

Print 
  1. ​Abdelmalek JA, Gansevoort RT, Lambers Heerspink HJ, Ix JH, Rifkin DE. Estimated albumin excretion rate versus urine albumin-creatinine ratio for the assessment of albuminuria: a diagnostic test study from the Prevention of Renal and Vascular Endstage Disease (PREVEND) Study. Am J Kidney Dis. 2014 Mar;63(3):415-21.
  2. Akkerman OW, van Altena R, Bolhuis MS, van der Werf TS, Alffenaar JW. Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response. Antimicrob Agents Chemother. 2014;58(1):628.
  3. Alffenaar JW, Gumbo T, Aarnoutse R. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015 Feb 5;372(6):576.
  4. Alffenaar JW, Gumbo T, Aarnoutse RE. Acquired Drug Resistance: We Can Do More  Than We Think! Clin Infect Dis. 2014 Dec 19.
  5. Alsaad N, Wilffert B, van Altena R, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J. 2014 Mar;43(3):884-97.
  6. Bello NA, Pfeffer MA, Skal H, McGill JB, Rossert J, Olson KA, Weinrauch L,  Cooper ME, de Zeeuw D, Rossing P, McMurray JJ, Solomon SD. Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Res Care. 2014 Apr 6;2(1):e000011.
  7. Berkhout MC, van Velzen AJ, Touw DJ, de Kok BM, Fokkens WJ, Heijerman HG. Systemic absorption of nasally administered tobramycin and colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2014 Nov;69(11):3112-5.
  8. Berm EJ, Brummel-Mulder E, Paardekooper J, Hak E, Wilffert B, Maring JG. Determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots for  TDM purposes, using LC-MS/MS. Anal Bioanal Chem. 2014 Apr;406(9-10):2349-53.
  9. Boessen R, Heerspink HJ, De Zeeuw D, Grobbee DE, Groenwold RH, Roes KC. Improving clinical trial efficiency by biomarker-guided patient selection. Trials. 2014 Apr 2;15:103.
  10. Bolhuis MS, van der Laan T, Kosterink JG, van der Werf TS, van Soolingen D, Alffenaar JW. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. Eur Respir J. 2014 Sep;44(3):808-11.
  11. Boorsma CE, Dekkers BG, van Dijk EM, Kumawat K, Richardson J, Burgess JK, John AE. Beyond TGFβ--novel ways to target airway and parenchymal fibrosis. Pulm  Pharmacol Ther. 2014 Dec;29(2):166-80.
  12. Broekmans AW, Mol PG. [The new pharmacovigilance legislation in practice].Ned Tijdschr Geneeskd. 2014;158:A7129. Dutch.
  13. Bruintjes JJ, Henning RH, Douwenga W, van der Zee EA. Hippocampal cystathionine beta synthase in young and aged mice. Neurosci Lett. 2014 Mar 20;563:135-9.
  14. Burger D, Krens S, Robijns K, Aarnoutse R, Brüggemann R, Touw D. Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/serum. Ther Drug Monit. 2014 Dec;36(6):824-7.
  15. Chertow GM, de Zeeuw D; BEACON Steering Committee. Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease. N Engl J Med. 2014 May 1;370(18):1768.
  16. Chin MP, Wrolstad D, Bakris GL, Chertow GM, de Zeeuw D, Goldsberry A, Linde PG, McCullough PA, McMurray JJ, Wittces J, Meyer CJ. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014 Dec;20(12):953-8.
  17. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS; CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014 Jun 25;311(24):2518-31.
  18. Dalbøge CS, Nielsen XC, Dalhoff K, Alffenaar JW, Duno M, Buchard A, Uges DR, Jensen AG, Jürgens G, Pressler T, Johansen HK, Høiby N. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2014 Mar;13(2):179-85.
  19. Damman K, Lambers-Heerspink HJ. Are renin-angiotensin-aldosterone system inhibitors lifesaving in chronic kidney disease? J Am Coll Cardiol. 2014 Feb 25;63(7):659-60.
  20. Daud AN, Bergman JE, Bakker MK, Wang H, de Walle HE, Plösch T, Wilffert B.Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. Pharmacogenomics. 2014 May;15(7):1029-41.
  21. Deetman PE, Bakker SJ, Kwakernaak AJ, Navis G, Dullaart RP; PREVEND Study Group. The relationship of the anti-oxidant bilirubin with free thyroxine is modified by insulin resistance in euthyroid subjects. PLoS One. 2014 Mar 3;9(3):e90886.
  22. Denig P, Schuling J, Haaijer-Ruskamp FM, Voorham J. Effects of a patient-oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. BMJ. 2014 Sep 25;349:g5651.
  23. Denig P, de Zeeuw D. New renal guidelines; is more better? Nephrol Dial Transplant. 2014 Apr;29(4):720-1.
  24. de Vries FM, Denig P, Visser ST, Hak E, Postma MJ. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands. Value Health. 2014 Mar;17(2):223-30.
  25. de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLoS One. 2014 Nov 5;9(11):e111247.
  26. de Vries ST, Haaijer-Ruskamp FM, de Zeeuw D, Denig P. Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study. Health Qual Life Outcomes. 2014 Aug 13;12:103.
  27. de Vries ST, Haaijer-Ruskamp FM, de Zeeuw D, Denig P. The validity of a patient-reported adverse drug event questionnaire using different recall periods. Qual Life Res. 2014 Nov;23(9):2439-45.
  28. de Vries ST, Keers JC, Visser R, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J, Denig P. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014 Feb;76(2):134-8.
  29. de Vries ST, Voorham J, Haaijer-Ruskamp FM, Denig P. Potential overtreatment and undertreatment of diabetes in different patient age groups in primary care after the introduction of performance measures. Diabetes Care. 2014 May;37(5):1312-20.
  30. de Vrij EL, Vogelaar PC, Goris M, Houwertjes MC, Herwig A, Dugbartey GJ, Boerema AS, Strijkstra AM, Bouma HR, Henning RH. Platelet dynamics during natural and pharmacologically induced torpor and forced hypothermia. PLoS One. 2014 Apr 10;9(4):e93218.
  31. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014 May;25(5):1083-93.
  32. de Zeeuw D, Lambers Heerspink H. Do diabetic kidneys deserve a lifestyle change? Lancet Diabetes Endocrinol. 2014 Oct;2(10):769-70.
  33. de Zeeuw D, Molitch ME. The authors reply. Kidney Int. 2014 Dec;86(6):1270.
  34. Dijkmans AC, Wilms EB, Kamerling IM, Birkhoff W, Ortiz-Zacarías NV, van Nieuwkoop C, Verbrugh HA, Touw DJ. Colistin: revival of an old polymyxin antibiotic. Ther Drug Monit. 2014 Dec 29.
  35. Dijkmans AC, Wilms EB, Kamerling IM, Birkhoff W, van Nieuwkoop C, Verbrugh HA, Touw DJ. [Practical guideline for the use of colistin]. Ned Tijdschr Geneeskd. 2014;158:A7445. Dutch.
  36. Dijkstra JA, Sturkenboom MG, Hateren Kv, Koster RA, Greijdanus B, Alffenaar JW. Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method. Bioanalysis. 2014 Aug;6(16):2125-33.
  37. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med. 2014 Feb 27;370(9):794-7.
  38. Garcia-Allende PB, Glatz J, Koch M, Tjalma JJ, Hartmans E, Terwisscha van Scheltinga AG, Symvoulidis P, van Dam GM, Nagengast WB, Ntziachristos V. Towards  clinically translatable NIR fluorescence molecular guidance for colonoscopy. Biomed Opt Express. 2013 Dec 4;5(1):78-92.
  39. Gaykema SB, de Jong JR, Perik PJ, Brouwers AH, Schröder CP, Oude Munnink TH, Bongaerts AH, de Vries EG, Lub-de Hooge MN. (111)In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment. Mol Imaging. 2014;13.
  40. Gaykema SB, Schröder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, Bongaerts AH, Akimov M, Fernandez-Ibarra C, Lub-de Hooge MN, de Vries EG, Swanton C, Banerji U. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res. 2014 Aug 1;20(15):3945-54.
  41. Gebhardtova A, Vavrinec P, Vavrincova-Yaghi D, Seelen M, Dobisova A, Flassikova Z, Cikova A, Henning RH, Yaghi A. A case of severe chlorite poisoning successfully treated with early administration of methylene blue, renal replacement therapy, and red blood cell transfusion: case report. Medicine (Baltimore). 2014 Aug;93(9):e60.
  42. Glaudemans AW, Bonanno E, Galli F, Zeebregts CJ, de Vries EF, Koole M, Luurtsema G, Boersma HH, Taurino M, Slart RH, Signore A. In vivo and in vitro evidence that 99m Tc-hynic-Interleukin-2 is able to detect T-lymphocytes in vulnerable artherosclerotic plaques of the carotid artery. EJNMMI 2014; 41: 210-9.
  43. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, Craig JC, de Zeeuw  D, Feldt-Rasmussen B, Fellström B, Levin A, Wheeler DC, Walker R, Herrington WG,  Baigent C, Landray MJ; SHARP Collaborative Group; SHARP Collaborative Group.Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014 Aug;25(8):1825-33.
  44. Haynes R, Staplin N, Emberson J, Herrington WG, Tomson C, Agodoa L, Tesar V, Levin A, Lewis D, Reith C, Baigent C, Landray MJ; SHARP Collaborative Group.Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis. 2014 Jul;64(1):40-8.
  45. Heerspink HJ, Grobbee DE, de Zeeuw D. A novel approach for establishing cardiovascular drug efficacy. Nat Rev Drug Discov. 2014 Dec;13(12):942.
  46. Heerspink HJ, de Zeeuw D. Are post-trial observational studies useful? J Am Soc Nephrol. 2014 Oct;25(10):2148-50.
  47. Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol. 2014 Mar;21(3):299-309.
  48. Helmons PJ, Kosterink JG, Daniels CE. Formulary compliance and pharmacy labor costs associated with systematic formulary management strategy. Am J Health Syst Pharm. 2014 Mar 1;71(5):407-15.
  49. Herrington W, Emberson J, Staplin N, Blackwell L, Fellström B, Walker R, Levin A, Hooi LS, Massy ZA, Tesar V, Reith C, Haynes R, Baigent C, Landray MJ; SHARP Investigators. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clin J Am Soc Nephrol. 2014 May;9(5):914-9.
  50. Hoekman J, Lambers Heerspink HJ, Viberti G, Green D, Mann JF, de Zeeuw D. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. Clin J Am Soc Nephrol. 2014 Mar;9(3):490-8.
  51. Huang Y, Zhou Q, Haaijer-Ruskamp FM, Postma MJ. Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review. BMC Nephrol. 2014 Jan 15;15:15.
  52. Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis. 2014 Dec;64(6):848-59.
  53. Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Early change in proteinuria  as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis. 2014 Jul;64(1):74-85.
  54. Ivanova SA, Geers LM, Al Hadithy AF, Pechlivanoglou P, Semke AV, Vyalova NM, Rudikov EV, Fedorenko OY, Wilffert B, Bokhan NA, Brouwers JR, Loonen AJ.Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:172-7.
  55. Jager NA, Westra J, Golestani R, van Dam GM, Low PS, Tio RA, Slart RH, Boersma HH, Bijl M, Zeebregts CJ. Folate receptor-β imaging using 99mTc-folate to explore distribution of polarized macrophage populations in human atherosclerotic plaque. J Nucl Med. 2014 Dec;55(12):1945-51.
  56. Janssen PK, Touw D, Schweitzer DH, Waldinger MD. Nonresponders to Daily Paroxetine and Another SSRI in Men With Lifelong Premature Ejaculation: A Pharmacokinetic Dose-Escalation Study for a Rare Phenomenon. Korean J Urol 2014; 55, 9, 599-607.
  57. Joosten MM, Gansevoort RT, Mukamal KJ, Lambers Heerspink HJ, Geleijnse JM, Feskens EJ, Navis G, Bakker SJ; PREVEND Study Group. Sodium excretion and risk of developing coronary heart disease. Circulation. 2014 Mar 11;129(10):1121-8.
  58. Juffermans LJ, Meijering BD, Henning RH, Deelman LE. Ultrasound and microbubble-targeted delivery of small interfering RNA into primary endothelial cells is more effective than delivery of plasmid DNA. Ultrasound Med Biol. 2014 Mar;40(3):532-40.
  59. Keijsers CJ, van Doorn AB, van Kalles A, de Wildt DJ, Brouwers JR, van de Kamp HJ, Jansen PA. Structured pharmaceutical analysis of the Systematic Tool to Reduce Inappropriate Prescribing is an effective method for final-year medical students to improve polypharmacy skills: a randomized controlled trial. J Am Geriatr Soc. 2014 Jul;62(7):1353-9.
  60. Klis S, Daskapan A, Akkerman OW, Alffenaar JW, Stienstra Y. Raltegravir and rifampicin in patients with HIV and tuberculosis. Lancet Infect Dis. 2014 Nov;14(11):1046-7.
  61. Kol A, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Lamberts LE, Bensch F, de Vries EG, Schröder CP. HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting. Pharmacol Ther. 2014 Jul;143(1):1-11.
  62. Koster RA, Alffenaar JW, Greijdanus B, VanDerNagel JE, Uges DR. Application of sweat patch screening for 16 drugs and metabolites using a fast and highly selective LC-MS/MS method. Ther Drug Monit. 2014 Feb;36(1):35-45.
  63. Koster RA, Alffenaar JW, Greijdanus B, VanDernagel JE, Uges DR. Fast and highly selective LC-MS/MS screening for THC and 16 other abused drugs and metabolites in human hair to monitor patients for drug abuse. Ther Drug Monit. 2014 Apr;36(2):234-43.
  64. Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, Groen H, Laverman GD, Navis G; Holland Nephrology Study (HONEST) Group. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol. 2014 May;2(5):385-95.
  65. Lagan BM, Dolk H, White B, Uges DR, Sinclair M. Assessing the availability of  the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies. Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):411-8.
  66. Lambers Heerspink HJ, Gaillard CJ, Gansevoort RT. Screening, monitoring, and  treatment of stage 1 to 3 chronic kidney disease. Ann Intern Med. 2014 Jul 1;161(1):82-3.
  67. Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, Coresh J, Levey AS, Inker LA. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am J Kidney  Dis. 2014 Dec;64(6):860-6.
  68. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis. 2014 Feb;63(2):244-50.
  69. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014 Jul;44(1):23-63.
  70. Lempers VJ, Alffenaar JW, Touw DJ, Burger DM, Uges DR, Aarnoutse RE, Brüggemann RJ. Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. J Antimicrob Chemother. 2014 Nov;69(11):2988-94.
  71. Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014 Dec;64(6):821-35.
  72. Lexis CP, van der Horst IC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel AF, van der Werf HW, Schurer RA, Pundziute G, Tan ES, Nieuwland W, Willemsen HM, Dorhout B, Molmans BH, van der Horst-Schrivers AN, Wolffenbuttel BH, ter Horst GJ, van Rossum AC, Tijssen JG, Hillege HL, de Smet BJ, van der Harst P, van Veldhuisen DJ; GIPS-III Investigators. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA. 2014 Apr 16;311(15):1526-35.
  73. Lexmond AJ, Hagedoorn P, van der Wiel E, Ten Hacken NH, Frijlink HW, de Boer AH. Adenosine dry powder inhalation for bronchial challenge testing, part 1: inhaler and formulation development and in vitro performance testing. Eur J Pharm Biopharm. 2014 Jan;86(1):105-14.
  74. Lexmond AJ, van der Wiel E, Hagedoorn P, Bult W, Frijlink HW, ten Hacken NH, de Boer AH. Adenosine dry powder inhalation for bronchial challenge testing, part 2: proof of concept in asthmatic subjects. Eur J Pharm Biopharm. 2014 Sep;88(1):148-52.
  75. Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, Boeree MJ, Donders AR, van Altena R, van der Werf TS, Aarnoutse RE. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Int J Antimicrob Agents. 2014 Sep;44(3):229-34.
  76. McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw  D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney  Dis. 2014 Nov;64(5):714-22.
  77. Mol PG, Maciulaitis R, Vetter T. GFR decline as an end point for clinical trials in CKD: a view from Europe. Am J Kidney Dis. 2014 Dec;64(6):838-40.
  78. Mol PG. Critically reviewing impact of regulatory actions, not just FDA's.Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):105.
  79. Nguyen HT, Nguyen TD, Haaijer-Ruskamp FM, Taxis K. Errors in preparation and administration of insulin in two urban Vietnamese hospitals: an observational study. Nurs Res. 2014 Jan-Feb;63(1):68-72.
  80. Nguyen HT, Pham HT, Vo DK, Nguyen TD, van den Heuvel ER, Haaijer-Ruskamp FM, Taxis K. The effect of a clinical pharmacist-led training programme on intravenous medication errors: a controlled before and after study. BMJ Qual Saf. 2014 Apr;23(4):319-24.
  81. Ochodnicky P, Mesarosova L, Cernecka H, Klimas J, Krenek P, Goris M, van Dokkum RP, Henning RH, Kyselovic J. Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat. Eur J Pharmacol. 2014 May 5;730:51-60.
  82. Pena MJ, Lambers Heerspink HJ, Hellemons ME, Friedrich T, Dallmann G, Lajer M, Bakker SJ, Gansevoort RT, Rossing P, de Zeeuw D, Roscioni SS. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet Med. 2014 Sep;31(9):1138-47.
  83. Pilmore H, Dogra G, Roberts M, Lambers Heerspink HJ, Ninomiya T, Huxley R, Perkovic V. Cardiovascular disease in patients with chronic kidney disease. Nephrology (Carlton). 2014 Jan;19(1):3-10.
  84. Qi XY, Diness JG, Brundel BJ, Zhou XB, Naud P, Wu CT, Huang H, Harada M, Aflaki M, Dobrev D, Grunnet M, Nattel S. Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. Circulation. 2014 Jan 28;129(4):430-40.
  85. Raphael MF, den Boer AM, Kollen WJ, Mekelenkamp H, Abbink FC, Kaspers GJ, Zomer-Kooijker K, Molmans BH, Tissing WJ. Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? : Results from a prospective multicenter double blind randomized controlled trial. Support Care Cancer. 2014 Jan;22(1):3-6.
  86. Riphagen IJ, Deetman PE, Bakker SJ, Navis G, Cooper ME, Lewis JB, de Zeeuw D, Lambers Heerspink HJ. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. Diabetes. 2014 Aug;63(8):2845-53.
  87. Robijns K, Koster RA, Touw DJ. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet. 2014 Nov;53(11):1053.
  88. Roman RJ, Van Dokkum RP. Commentary on the special issue on the impact of myogenic tone in health and disease. Curr Vasc Pharmacol. 2014;12(6):779.
  89. Romero K, Sinha V, Allerheiligen S, Danhof M, Pinheiro J, Kruhlak N, Wang Y,  Wang SJ, Sauer JM, Marier JF, Corrigan B, Rogers J, Lambers Heerspink HJ, Gumbo T, Vis P, Watkins P, Morrison T, Gillespie W, Gordon MF, Stephenson D, Hanna D, Pfister M, Lalonde R, Colatsky T. Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. J  Pharmacokinet Pharmacodyn. 2014 Dec;41(6):545-52.
  90. Roscioni SS, Heerspink HJ, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol. 2014 Feb;10(2):77-87.
  91. Roscioni SS, Lambers Heerspink HJ, de Zeeuw D. Microalbuminuria: target for renoprotective therapy PRO. Kidney Int. 2014 Jul;86(1):40-9.
  92. Sahinovic MM, Beese U, Heeremans EH, Kalmar A, van Amsterdam K, Steenbakkers RJ, Kuiper H, Spanjersberg R, Groen RJ, Struys MM, Absalom AR. Bispectral index values and propofol concentrations at loss and return of consciousness in patients with frontal brain tumours and control patients. Br J Anaesth. 2014 Jan;112(1):110-7
  93. Samarska IV, Bouma HR, Buikema H, Mungroop HE, Houwertjes MC, Absalom AR, Epema AH, Henning RH. S1P1 receptor modulation preserves vascular function in mesenteric and coronary arteries after CPB in the rat independent of depletion of lymphocytes. PLoS One. 2014 May 12;9(5):e97196.
  94. Schievink B, Lambers Heerspink H, Leufkens H, De Zeeuw D, Hoekman J. The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders. PLoS One. 2014 Sep 30;9(9):e108722.
  95. Schiphorst Preuper HR, Geertzen JH, van Wijhe M, Boonstra AM, Molmans BH, Dijkstra PU, Reneman MF. Do analgesics improve functioning in patients with chronic low back pain? An explorative triple-blinded RCT. Eur Spine J. 2014 Apr;23(4):800-6.
  96. Setiawan D, Luttjeboer J, Westra TA, Wilschut JC, Suwantika AA, Daemen T, Atthobari J, Wilffert B, Postma MJ. The cost-effectiveness of HPV vaccination in  addition to screening: a Dutch perspective. Expert Rev Vaccines. 2014 Dec 6:1-16.
  97. Sidorenkov G, Navis G. Safety of ACE inhibitor therapies in patients with chronic kidney disease. Expert Opin Drug Saf. 2014 Oct;13(10):1383-95
  98. Smink PA, Hoekman J, Grobbee DE, Eijkemans MJ, Parving HH, Persson F, Ibsen H, Lindholm L, Wachtell K, de Zeeuw D, Heerspink HJ. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. Eur J Prev Cardiol. 2014 Apr;21(4):434-41.
  99. Smink PA, Miao Y, Eijkemans MJ, Bakker SJ, Raz I, Parving HH, Hoekman J, Grobbee DE, de Zeeuw D, Lambers Heerspink HJ. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clin Pharmacol Ther. 2014 Feb;95(2):208-15
  100. Sundström J, Arima H, Woodward M, Jackson R, Karmali K, Lloyd-Jones D, Baigent C, Emberson J, Rahimi K, MacMahon S, Patel A, Perkovic V, Turnbull F, Neal B. Blood Pressure Lowering Treatment Trialists' Collaboration, Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014 Aug 16;384(9943):591-8.
  101. Tahara N, Mukherjee J, de Haas HJ, Petrov AD, Tawakol A, Haider N, Tahara A, Constantinescu CC, Zhou J, Boersma HH, Imaizumi T, Nakano M, Finn A, Fayad Z, Virmani R, Fuster V, Bosca L, Narula J. 2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis. Nat Med. 2014 Feb;20(2):215-9.
  102. Talaei F, Van Praag VM, Shishavan MH, Landheer SW, Buikema H, Henning RH. Increased protein aggregation in Zucker diabetic fatty rat brain: identification of key mechanistic targets and the therapeutic application of hydrogen sulfide. BMC Cell Biol. 2014 Jan 6;15:1.
  103. Terwisscha van Scheltinga AG, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot  L, Gaykema SB, Lub-de Hooge MN, Kosterink JG, de Vries EG, Schröder CP. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer. Eur J Cancer. 2014 Sep;50(14):2508-16.
  104. Terwisscha van Scheltinga AG, Lub-de Hooge MN, Abiraj K, Schröder CP, Pot L,  Bossenmaier B, Thomas M, Hölzlwimmer G, Friess T, Kosterink JG, de Vries EG.ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116. MAbs. 2014 Jul-Aug;6(4):1051-8.
  105. Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer. J Nucl Med. 2014 Apr;55(4):665-71.
  106. Thomassen BJ, Touw D, van der Woude P, van der Flier RE, In 't Veld BA. Safety of blood reinfusion after local infiltration analgesia with ropivacaine in total knee arthroplasty. Int J Clin Pharmacol Ther. 2014 Feb;52(2):135-42.
  107. van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AH, de Jong JR, Lub-de Hooge MN, Oude Munnink TH, Fiebrich HB, Sluiter WJ, Links TP, Walenkamp AM, de Vries EG. Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors. J Nucl Med. 2014 May 1;55(7):1087-1092.
  108. van der Elst KC, Pereboom M, van den Heuvel ER, Kosterink JG, Schölvinck EH,  Alffenaar JW. Insufficient fluconazole exposure in pediatric cancer patients and  the need for therapeutic drug monitoring in critically ill children. Clin Infect  Dis. 2014 Dec 1;59(11):1527-33.
  109. van der Elst KC, van Alst M, Lub-de Hooge MN, van Hateren K, Kosterink JG, Alffenaar JW, Schölvinck EH. Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children. Antimicrob Agents Chemother. 2014 Nov;58(11):6742-6.
  110. van Maarseveen E, van Buul-Gast MC, Abdoellakhan R, Gelinck L, Neef C, Touw D.Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients. J Antimicrob Chemother. 2014 Sep;69(9):2581-3.
  111. van Maarseveen EM, Bouma A, Touw DJ, Neef C, van Zanten AR. Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach. Eur J Clin Pharmacol. 2014 Nov;70(11):1353-9.
  112. van Rijn SP, Wessels AM, Greijdanus B, Touw DJ, Alffenaar JW. Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method. Antimicrob Agents Chemother. 2014 Jun;58(6):3481-4.
  113. van Velzen AJ, Berkhout MC, Touw DJ, De Kok BM, Heijerman HGM. Pharmacokinetics of nasally administered tobramycin, colistin sulphomethate sodium and a combination of tobramycin and colistin sulphomethate sodium. J Cyst Fibros 2014; 13, 57.
  114. van Wanrooy MJ, Rodgers MG, Uges DR, Arends JP, Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar JW. Low but sufficient anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother. 2014;58(1):304-8.
  115. van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014 Dec;58(12):7098-101.
  116. Vavrinec P, Henning RH, Landheer SW, Wang Y, Deelman LE, Dokkum RP, Buikema H. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat. Curr Vasc Pharmacol. 2014;12(6):836-44.
  117. Vermeulen KM, van Doormaal JE, Zaal RJ, Mol PG, Lenderink AW, Haaijer-Ruskamp FM, Kosterink JG, van den Bemt PM. Cost-effectiveness of an electronic medication ordering system (CPOE/CDSS) in hospitalized patients. Int J Med Inform. 2014 Aug;83(8):572-80.
  118. Vimaleswaran KS, Cavadino A, Berry DJ; LifeLines Cohort Study investigators, Jorde R, Dieffenbach AK, Lu C, Alves AC, Heerspink HJ, Tikkanen E, Eriksson J, Wong A, Mangino M, Jablonski KA, Nolte IM, Houston DK, Ahluwalia TS, van der Most PJ, Pasko D, Zgaga L, Thiering E, Vitart V, Fraser RM, Huffman JE, de Boer RA, Schöttker B, Saum KU, McCarthy MI, Dupuis J, Herzig KH, Sebert S, Pouta A,Laitinen J, Kleber ME, Navis G, Lorentzon M, Jameson K, Arden N, Cooper JA, Acharya J, Hardy R, Raitakari O, Ripatti S, Billings LK, Lahti J, Osmond C, Penninx BW, Rejnmark L, Lohman KK, Paternoster L, Stolk RP, Hernandez DG, Byberg L, Hagström E, Melhus H, Ingelsson E, Mellström D, Ljunggren O, Tzoulaki I, McLachlan S, Theodoratou E, Tiesler CM, Jula A, Navarro P, Wright AF, Polasek O; International Consortium for Blood Pressure (ICBP); Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium; Global Blood Pressure Genetics (Global BPGen) consortium; Caroline Hayward, Wilson JF, Rudan I, Salomaa V, Heinrich J, Campbell H, Price JF, Karlsson M, Lind L, Michaëlsson K, Bandinelli S, Frayling TM, Hartman CA, Sørensen TI, Kritchevsky SB, Langdahl BL, Eriksson JG, Florez JC, Spector TD, Lehtimäki T, Kuh D, Humphries SE, Cooper C, Ohlsson C, März W, de Borst MH, Kumari M, Kivimaki M, Wang TJ, Power C, Brenner H, Grimnes G, van der Harst P, Snieder H, Hingorani AD, Pilz S, Whittaker JC, Järvelin MR, Hyppönen E. Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2014 Sep;2(9):719-29.
  119. Vu DH, Koster RA, Bolhuis MS, Greijdanus B, Altena RV, Nguyen DH, Brouwers JR, Uges DR, Alffenaar JW. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. Talanta. 2014 Apr;121:9-17.
  120. Warnier MJ, Holtkamp FA, Rutten FH, Hoes AW, de Boer A, Mol PG, De Bruin ML. Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling. Drug Discov Today. 2014 Sep;19(9):1294-7.
  121. Warnier MJ, Holtkamp FA, Rutten FH, Hoes AW, de Boer A, Mol PG, De Bruin ML. Quality of drug label information on QT interval prolongation. Int J Risk Saf Med. 2014;26(2):89-98.
  122. Wen CP, Matsushita K, Coresh J, Iseki K, Islam M, Katz R, McClellan W, Peralta CA, Wang H, de Zeeuw D, Astor BC, Gansevoort RT, Levey AS, Levin A; Chronic Kidney Disease Prognosis Consortium. Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney Int. 2014 Oct;86(4):819-27.
  123. Wright DB, Meurs H, Dekkers BG. Integrins: therapeutic targets in airway hyperresponsiveness and remodelling? Trends Pharmacol Sci. 2014 Nov;35(11):567-74.
  124. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, Vijapurkar U, Kline I, Usiskin K, Meininger G, Bakris G. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40(1):64-74.
  125. Zhang D, Wu CT, Qi X, Meijering RA, Hoogstra-Berends F, Tadevosyan A, Cubukcuoglu Deniz G, Durdu S, Akar AR, Sibon OC, Nattel S, Henning RH, Brundel BJ. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation. Circulation. 2014 Jan 21;129(3):346-58.